Investigating serotonergic function using positron emission tomography: Overview and recent findings

Current Pharmaceutical Design

Volumn 16, Issue 18, 2010, Pages 1979-1989

  Veltman, D J ^a,c   Ruhe, H G ^a   Booij, J ^b  

^a Depts of Psychiatry   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer; Depression; Epilepsy; Positron emission tomography; Schizophrenia; Serotonin

Indexed keywords

1,2,3,5,6,10B HEXAHYDRO 6 (4 METHYLTHIOPHENYL)PYRROLO[2,1 A]ISOQUINOLINE; 1,2,3,5,6,10B HEXAHYDRO 6 (4 METHYLTHIOPHENYL)PYRROLO[2,1 A]ISOQUINOLINE C 11; 3 (2 FLUOROETHYL) 8 [4 (4 FLUOROPHENYL) 4 OXOBUTYL] 1 PHENYL 1,3,8 TRIAZASPIRO[4.5]DECAN 4 ONE F 18; 3 AMINO 4 [[2 [(DIMETHYLAMINO)METHYL]PHENYL]THIO]BENZONITRILE C 11; 6 [2 [4 (4 FLUOROBENZOYL) 1 PIPERIDINYL]ETHYL] 2,3 DIHYDRO 7 METHYL 5H THIAZOLO [3,2 A]PYRIMIDIN 5 ONE F 18; ALTANSERIN F 18; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE C 11; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE F 18; OLANZAPINE; RACLOPRIDE C 11; RADIOLIGAND; RISPERIDONE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRACER; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VOLINANSERIN; VOLINANSERIN C 11; ZIPRASIDONE;

ALZHEIMER DISEASE; ANXIETY DISORDER; ARTICLE; COGNITIVE THERAPY; DRUG MECHANISM; DRUG RECEPTOR BINDING; ELECTROCONVULSIVE THERAPY; GENERALIZED ANXIETY DISORDER; HUMAN; MAJOR DEPRESSION; NERVE CELL NETWORK; NERVE CONDUCTION; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PANIC; PATHOPHYSIOLOGY; PHOBIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOTHERAPY; SCHIZOPHRENIA; SEROTONINERGIC NERVE CELL; SEROTONINERGIC SYSTEM; SEROTONINERGIC TRANSMISSION; TEMPORAL LOBE EPILEPSY; ANIMAL; MENTAL DISEASE; METABOLISM; PROCEDURES; SENSITIVITY AND SPECIFICITY;

ANIMALS; HUMANS; MENTAL DISORDERS; POSITRON-EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; SEROTONIN;

EID: 77953502557     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210791293033     Document Type: Article

References (156)

1. Siegel GJ, Agranoff BW, Albers RW, Fisher SK, Uhler MD. Basic neurochemistry, molecular, cellular, and medical aspects. 6th ed. Philadelphia: Lippincott, Williams & Wilkins 1999.
2. Purves D, Augustine G, Fitzpatrick D, Katz L, LaMantia A. Neuroscience. 2nd ed. Sunderland: Sinauer Associates, Inc. 2001.
3. Andreasen NC. Brave new brain: conquering mental illness in the era of the genome. Schitterend nieuw brein: psychiatrie in het tijdperk van het genoom. 1st ed. Amsterdam: Nieuwezijds BV; 2002.
4. Marieb E. Human anatomy & Physiology. 5th ed. Redwood City: The Benjamin/Cummings Publishing Company, Inc. 1999.
5. Gaspar P, Cases O, Maroteaux L. The developmental role of serotonin: news from mouse molecular genetics. Nat Rev Neurosci 2003; 4: 1002-12.
6. Martinowich K, Lu B. Interaction between BDNF and serotonin: role in mood disorders. Neuropsychopharmacology 2008; 33: 73-83.
7. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007; 27(9): 1533-9.
8. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage 1996; 4(3 Pt 1): 153-8.
9. Kumar JS, Mann JJ. PET tracers for 5-HT(1A) receptors and uses thereof. Drug Discov Today 2007; 12(17-18): 748-56.
10. Aznavour N, Zimmer L. [18F]MPPF as a tool for the in vivo imaging of 5-HT1A receptors in animal and human brain. Neuropharmacology 2007; 52: 695-707.
11. Smith DF, Jakobsen S. Molecular tools for assessing human depression by positron emission tomography. Eur Neuropsychopharmacol 2009; 19(9): 611-28.
12. Marner L, Gillings N, Comley RA, Baaré WF, Rabiner EA, Wilson AA, Kinetic modeling of 11C-SB207145 binding to 5-HT4 receptors in the human brain in vivo. J Nucl Med 2009; 50(6): 900-8.
13. Berger M, Gray JA, Roth BL. The expanded biology of serotonin. Annu Rev Med 2009; 60: 355-66.
14. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289(23): 3095-105.
15. Friedman MA, Detweiler-Bedell JB, Leventhal HE, Horne R, Keitner GI, Miller IW. Combined psychotherapy and pharmaco-therapy for the treatment of major depressive disorder. Clin Psychol Sci Pract 2004; 11: 47-68.
16. Damasio AR. Descartes' error -emotion, reason and the human brain. De vergissing van Descartes -gevoel, verstand en het menselijk brein. 2nd ed. Amsterdam: Wereldbibliotheek; 1994.
17. Cowen P. Trends Pharmacol Sci 2008; 29: 433-6.
18. Owens MJ. Selectivity of antidepressants: from the monoamine hypothesis of depression to the SSRI revolution and beyond. J Clin Psychiatry 2004; 65 (Suppl 4): 5-10.
19. Burke WJ. Selective versus multi-transmitter antidepressants: are two mechanisms better than one? J Clin Psychiatry 2004; 65 (Suppl 4): 37-45.
20. Fava M, Kendler KS. Major depressive disorder. Neuron 2000; 28: 335-341.
21. Delgado PL. How antidepressants help depression: mechanisms of action and clinical response. J Clin Psychiatry 2004; 65 (Suppl 4): 25-30.
22. Blier P, De Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci 1994; 15: 220-6.
23. Nemeroff CB, Owens MJ. Neuropharmacology of paroxetine. Psychopharmacol Bull 2003; 37 (Suppl 1): 8-18.
24. Benmansour S, Cecchi M, Morilak DA, Gerhardt GA, Javors MA, Gould GG, et al. Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level. J Neurosci 1999; 19: 10494-501.
25. Benmansour S, Owens WA, Cecchi M, Morilak DA, Frazer A. Serotonin clearance in vivo is altered to a greater extent by antidepressant-induced downregulation of the serotonin transporter than by acute blockade of this transporter. J Neurosci 2002; 22: 6766-72.
26. Pineyro G, Blier P, Dennis T, De Montigny C. Desensitization of the neuronal 5-HT carrier following its long-term blockade. J Neurosci 1994; 14: 3036-47.
27. Maj J, Bijak M, Dziedzicka-Wasylewska M, Rogoz R, Rogoz Z, Skuza G, et al. The effects of paroxetine given repeatedly on the 5-HT receptor subpopulations in the rat brain. Psychopharmacology (Berl) 1996; 127: 73-82.
28. Whale R, Clifford EM, Bhagwagar Z, Cowen PJ. Decreased sensitivity of 5-HT1D receptors in melancholic depression. Br J Psychiatry 2001; 178: 454-7.
29. Kennett GA, Lightowler S, de Biasi V, Stevens NC, Wood MD, Tulloch IF, et al. Effect of chronic administration of selective 5-hydroxytryptamine and noradrenaline uptake inhibitors on a putative index of 5-HT2C/2B receptor function. Neuropharmacology 1994; 33: 1581-8.
30. [30] Vaswani M, Linda FK, Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 85-102.
31. Djavadian RL. Serotonin and neurogenesis in the hippocampal dentate gyrus of adult mammals. Acta Neurobiol Exp (Wars) 2004; 64: 189-200.
32. Hu XZ, Lipsky RH, Zhu G, Akhtar LA, Taubman J, Greenberg BD, et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet 2006; 78: 815-26.
33. Lesch KP, Gutknecht L. Pharmacogenetics of the serotonin transporter. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 1062-73.
34. Serretti A, Kato M, De Ronchi D, Kinoshita T. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 2007; 12: 247-57.
35. Hu XZ, Rush AJ, Charney D, Wilson AF, Sorant AJ, Papanicolaou GJ, et al. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry 2007; 64: 783-92.
36. Kraft JB, Peters EJ, Slager SL, Jenkins GD, Reinalda MS, McGrath PJ, et al. Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample. Biol Psychiatry 2007; 61: 734-42.
37. Murphy DL, Lerner A, Rudnick G, Lesch KP. Serotonin transporter: gene, genetic disorders, and pharmacogenetics. Mol Interv 2004; 4: 109-23.
38. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003; 301: 386-9.
39. Hariri AR, Mattay VS, Tessitore A, Kolachana B, Fera F, Goldman D, et al. Serotonin transporter genetic variation and the response of the human amygdala. Science 2002; 297: 400-3.
40. Hariri AR, Drabant EM, Munoz KE, Kolachana BS, Mattay VS, Egan MF, et al. A susceptibility gene for affective disorders and the response of the human amygdala. Arch Gen Psychiatry 2005; 62: 146-52.
41. Pezawas L, Meyer-Lindenberg A, Drabant EM, Verchinski BA, Munoz KE, Kolachana BS, et al. 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression. Nat Neurosci 2005; 8: 828-34.
42. Drevets WC, Frank E, Price JC, Kupfer DJ, Holt D, Greer PJ, et al. PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry 1999; 46(10): 1375-87.
43. Drevets WC, Thase ME, Moses-Kolko EL, Price J, Frank E, Kupfer DJ, et al. Serotonin-1A receptor imaging in recurrent depression: replication and literature review. Nucl Med Biol 2007; 34(7): 865-77.
44. Sargent PA, Kjaer KH, Bench CJ, Rabiner EA, Messa C, Meyer J, et al. Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry 2000; 57(2): 174-80.
45. Bhagwagar Z, Rabiner EA, Sargent PA, Grasby PM, Cowen PJ. Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635. Mol Psychiatry 2004; 9(4): 386-92.
46. [46] Hirvonen J, Karlsson H, Kajander J, Lepola A, Markkula J, Rasi-Hakala HDecreased brain serotonin 5-HT1A receptor availability in medication-naive patients with major depressive disorder: an in-vivo imaging study using PET and [carbonyl-11C]WAY-100635. Int J Neuropsychopharmacol 2008; 11(4): 465-76.
47. Moses-Kolko EL, Price JC, Thase ME, Meltzer CC, Kupfer DJ, Mathis CA, et al. Measurement of 5-HT1A receptor binding in depressed adults before and after antidepressant drug treatment using positron emission tomography and [11C]WAY-100635. Synapse 2007; 61(7): 523-30.
48. Parsey RV, Olvet DM, Oquendo MA, Huang YY, Ogden RT, Mann JJ. Higher 5-HT1A receptor binding potential during a major depressive episode predicts poor treatment response: preliminary data from a naturalistic study. Neuropsychopharmacology 2006; 31(8): 1745-9.
49. Parsey RV, Oquendo MA, Ogden RT, Olvet DM, Simpson N, Huang YY, et al. Altered serotonin 1A binding in major Veltman et al. depression: a [carbonyl-C-11]WAY100635 positron emission tomography study. Biol Psychiatry 2006; 59(2): 106-13.
50. Miller JM, Brennan KG, Ogden TR, Oquendo MA, Sullivan GM, Mann JJ, et al. Elevated serotonin 1A binding in remitted major depressive disorder: evidence for a trait biological abnormality. Neuropsychopharmacology 2009; 34(10): 2275-84.
51. Biver F, Wikler D, Lotstra F, Damhaut P, Goldman S, Mendlewicz J. Serotonin 5-HT2 receptor imaging in major depression: focal changes in orbito-insular cortex. Br J Psychiatry 1997; 171: 444-8.
52. [52] Mann JJ, Arango V, Marzuk PM, Theccanat S, Reis DJ. Evidence for the 5-HT hypothesis of suicide. A review of post-mortem studies. Br J Psychiatry Suppl 1989; (8): 7-14.
53. Meyer JH, Kapur S, Houle S, DaSilva J, Owczarek B, Brown GM, et al. Prefrontal cortex 5-HT2 receptors in depression: an [18F] setoperone PET imaging study. Am J Psychiatry 1999; 156(7): 1029-34.
54. Attar-Lévy D, Martinot JL, Blin J, Dao-Castellana MH, Crouzel C, Mazoyer B, et al. The cortical serotonin2 receptors studied with positron-emission tomography and [18F]-setoperone during depressive illness and antidepressant treatment with clomipramine. Biol Psychiatry 1999; 45(2): 180-6.
55. Yatham LN, Liddle PF, Dennie J, Shiah IS, Adam MJ, Lane CJ, et al. Decrease in brain serotonin 2 receptor binding in patients with major depression following desipramine treatment: a positron emission tomography study with fluorine-18-labeled setoperone. Arch Gen Psychiatry 1999; 56(8): 705-11.
56. Meyer JH, McMain S, Kennedy SH, Korman L, Brown GM, DaSilva JN, et al. Dysfunctional attitudes and 5-HT2 receptors during depression and self-harm. Am J Psychiatry 2003; 160(1): 90-9.
57. Parsey RV, Kegeles LS, Hwang DR, Simpson N, Abi-Dargham A, Mawlawi O, et al. In vivo quantification of brain serotonin transporters in humans using [11C]McN 5652. J Nucl Med 2000; 41(9): 1465-77.
58. Frankle WG, Huang Y, Hwang DR, Talbot PS, Slifstein M, Van Heertum R, et al. Comparative evaluation of serotonin transporter radioligands 11C-DASB and 11C-McN 5652 in healthy humans. J Nucl Med 2004; 45(4): 682-94.
59. Ichimiya T, Suhara T, Sudo Y, Okubo Y, Nakayama K, Nankai M, et al. Serotonin transporter binding in patients with mood disorders: a PET study with [11C](+)McN5652. Biol Psychiatry 2002; 51(9): 715-22.
60. Reivich M, Amsterdam JD, Brunswick DJ, Shiue CY. PET brain imaging with [11C](+)McN5652 shows increased serotonin transporter availability in major depression. J Affect Disord 2004; 82(2): 321-7.
61. Meyer JH, Houle S, Sagrati S, Carella A, Hussey DF, Ginovart N, et al. Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes. Arch Gen Psychiatry 2004; 61(12): 1271-9.
62. Cannon DM, Ichise M, Rollis D, Klaver JM, Gandhi SK, Charney DS, et al. Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [11C]DASB; comparison with bipolar disorder. Biol Psychiatry 2007; 62(8): 870-7.
63. Cannon DM, Ichise M, Fromm SJ, Nugent AC, Rollis D, Gandhi SK, et al. Serotonin transporter binding in bipolar disorder assessed using [11C]DASB and positron emission tomography. Biol Psychiatry 2006; 60(3): 207-17.
64. Parsey RV, Hastings RS, Oquendo MA, Huang YY, Simpson N, Arcement J, et al. Lower serotonin transporter binding potential in the human brain during major depressive episodes. Am J Psychiatry 2006; 163(1): 52-8.
65. Miller JM, Oquendo MA, Ogden RT, Mann JJ, Parsey RV. Serotonin transporter binding as a possible predictor of one-year remission in major depressive disorder. J Psychiatr Res 2008; 42(14): 1137-44.
66. Bhagwagar Z, Murthy N, Selvaraj S, Hinz R, Taylor M, Fancy S, et al. 5-HTT binding in recovered depressed patients and healthy volunteers: a positron emission tomography study with [11C]DASB. Am J Psychiatry 2007; 164(12): 1858-65.
67. Reimold M, Batra A, Knobel A, Smolka MN, Zimmer A, Mann K, Anxiety is associated with reduced central serotonin transporter availability in unmedicated patients with unipolar major Investigating Serotonergic Function Using Positron Emission Tomography depression: a [11C]DASB PET study. Mol Psychiatry 2008; 13(6): 606-13, 557.
68. Frokjaer VG, Vinberg M, Erritzoe D, Svarer C, Baaré W, Budtz-Joergensen E, et al. High familial risk for mood disorder is associated with low dorsolateral prefrontal cortex serotonin transporter binding. Neuroimage 2009; 46(2): 360-6.
69. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, et al. Prevalence of mental disorders in europe: results from the european study of the epidemiology of mental disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 2004; 420: 21-7.
70. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th revised ed. APA 2000.
71. Kolada JL, Bland RC, Newman SC. Obsessive-compulsive disorder. Acta Psychiatrica Scandinavica 1994; 376(Suppl): 24-35.
72. Goodman WK, McDougle CJ, Price LH, Riddle MA, Pauls DL, Leckman JF. Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive-compulsive disorder? J Clin Psychiatry 1990; 51(Suppl 8): 36-43.
73. McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH. A double-blind, placebo-controlled study of risperdone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000; 57: 794-801.
74. Adams KH, Hansen ES, Pinborg LH, Hasselbalch SG, Svarer C, Holm S, et al. Patients with obsessive-compulsive disorder have increased 5-HT2A receptor binding in the caudate nuclei. Int J Neuropsychopharmacol 2005; 8(3): 391-401.
75. Perani D, Garibotto V, Gorini A, Moresco RM, Henin M, Panzacchi A, et al. In vivo PET study of 5HT(2A) serotonin and D(2) dopamine dysfunction in drug-naive obsessive-compulsive disorder. Neuroimage 2008; 42(1): 306-14.
76. Westenberg HG, Fineberg NA, Denys D. Neurobiology of obsessive-compulsive disorder: serotonin and beyond. CNS Spectrosc 2007; 12(2 Suppl 3): 14-27.
77. Moresco RM, Pietra L, Henin M, Panzacchi A, Locatelli M, Bonaldi L, et al. Fluvoxamine treatment and D2 receptors: a pet study on OCD drug-naïve patients. Neuropsychopharmacology 2007; 32(1): 197-205.
78. Simpson HB, Lombardo I, Slifstein M, Huang HY, Hwang DR, Abi-Dargham A, et al. Serotonin transporters in obsessive-compulsive disorder: a positron emission tomography study with [(11)C]McN 5652. Biol Psychiatry 2003; 54(12): 1414-21.
79. Reimold M, Smolka MN, Zimmer A, Batra A, Knobel A, Solbach C, et al. Reduced availability of serotonin transporters in obsessive-compulsive disorder correlates with symptom severity -a [11C]DASB PET study. J Neural Transm 2007; 114(12): 1603-9.
80. Matsumoto R, Ichise M, Ito H, Ando T, Takahashi H, Ikoma Y, et al. Reduced serotonin transporter binding in the insular cortex in patients with obsessive-compulsive disorder: a [11C]DASB PET study. Neuroimage 2010; 49(1): 121-6.
81. El Mansari M, Blier P. Responsiveness of 5-HT(1A) and 5-HT2 receptors in the rat orbitofrontal cortex after long-term serotonin reuptake inhibition. J Psychiatr Neurosci 2005; 30(4): 268-74.
82. Klein DF. False suffocation alarms, spontaneous panics, and related conditions: an integrative hypothesis. Arch Gen Psychiatry 1993; 50: 306-17.
83. Veltman DJ, van Zijderveld GA, van Dyck R, Bakker A. Predictability, controllability, and fear of symptoms of anxiety in epinephrine-induced panic. Biol Psychiatry 1998; 44(10): 1017-26.
84. Gorman JM, Kent JM, Sullivan GM, Coplan JD. Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry 2000; 157(4): 493-505.
85. Malizia AL, Cunningham VJ, Bell CJ, Liddle PF, Jones T, Nutt DJ. Decreased brain GABAa-benzodiazepine receptor binding in panic disorder. Arch Gen Psychiatry 1998; 55: 715-20.
86. Hasler G, Nugent AC, Carlson PJ, Carson RE, Geraci M, Drevets WC. Altered cerebral gamma-aminobutyric acid type A-benzodiazepine receptor binding in panic disorder determined by [11C]flumazenil positron emission tomography. Arch Gen Psychiatry 2008; 65(10): 1166-75.
87. Neumeister A, Bain E, Nugent AC, Carson RE, Bonne O, Luckenbaugh DA, et al. Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci 2004; 24: 589-591.
88. Nash JR, Sargent PA, Rabiner EA, Hood SD, Argyropoulos SV, Potokar JP, et al. Serotonin 5-HT1A receptor binding in people with panic disorder: positron emission tomography study. Br J Psychiatry 2008; 193(3): 229-34.
89. Lanzenberger RR, Mitterhauser M, Spindelegger C, Wadsak W, Klein N, Mien LK, et al. Reduced serotonin-1A receptor binding in social anxiety disorder. Biol Psychiatry 2007; 61(9): 1081-9.
90. Bradley R, Greene J, Russ E, Dutra L, Westen D. A multi-dimensional meta-analysis of psychotherapy for PTSD. Am J Psychiatry 2005; 162(2): 214-27.
91. Donnelly CL. Pharmacologic treatment approaches for children and adolescents with posttraumatic stress disorder. Child Adolesc Psychiatr Clin N Am 2003; 12(2): 251-69.
92. Karl A, Werner A. The use of proton magnetic resonance spectroscopy in PTSD research--meta-analyses of findings and methodological review. Neurosci Biobehav Rev 2010; 34(1): 7-22.
93. Bonne O, Bain E, Neumeister A, Nugent AC, Vythilingam M, Carson RE, et al. Am J Psychiatry 2005; 162(2): 383-5.
94. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991; 148(11): 1474-86.
95. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III--the final common pathway. Schizophr Bull 2009; 35(3): 549-62.
96. Bantick RA, Deakin JF, Grasby PM. The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? J Psychopharmacol 2001; 15(1): 37-46.
97. Nordström AL, Farde L, Halldin C. High 5-HT2 receptor occupancy in clozapine treated patients demonstrated by PET. Psychopharmacology (Berl) 1993; 110(3): 365-7.
98. Farde L, Nordström AL, Nyberg S, Halldin C, Sedvall G. D1-, D2-, and 5-HT2-receptor occupancy in clozapine-treated patients. J Clin Psychiatry 1994; 55 (Suppl B): 67-9.
99. Farde L, Nyberg S, Oxenstierna G, Nakashima Y, Halldin C, Ericsson B. Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients. J Clin Psychopharmacol 1995; 15(Suppl 1): 19S-23.
100. Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA, et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 1998; 155(7): 921-8.
101. Mamo D, Kapur S, Shammi CM, Papatheodorou G, Mann S, Therrien F, et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry 2004; 161(5): 818-25.
102. Trichard C, Paillère-Martinot ML, Attar-Levy D, Recassens C, Monnet F, Martinot JL. Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients. Am J Psychiatry 1998; 155(4): 505-8.
103. Trichard C, Paillère-Martinot ML, Attar-Levy D, Blin J, Feline A, Martinot JL. No serotonin 5-HT2A receptor density abnormality in the cortex of schizophrenic patients studied with PET. Schizophr Res 1998; 31(1): 13-7.
104. Lewis R, Kapur S, Jones C, DaSilva J, Brown GM, Wilson AA, et al. Serotonin 5-HT2 receptors in schizophrenia: a PET study using [18F]setoperone in neuroleptic-naive patients and normal subjects. Am J Psychiatry 1999; 156(1): 72-8.
105. Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, et al. Serotonin 5-HT2 receptors in schizophrenic patients studied by positron emission tomography. Life Sci 2000; 66(25): 2455-64.
106. Verhoeff NP, Meyer JH, Kecojevic A, Hussey D, Lewis R, Tauscher J, et al. A voxel-by-voxel analysis of [18F]setoperone PET data shows no substantial serotonin 5-HT(2A) receptor changes in schizophrenia. Psychiatr Res 2000; 99(3): 123-35.
107. Ngan ET, Yatham LN, Ruth TJ, Liddle PF. Decreased serotonin 2A receptor densities in neuroleptic-naive patients with schizophrenia: a PET study using [(18)F]setoperone. Am J Psychiatry 2000; 157(6): 1016-8.
108. Hurlemann R, Boy C, Meyer PT, Scherk H, Wagner M, Herzog H, et al. Decreased prefrontal 5-HT2A receptor binding in subjects at enhanced risk for schizophrenia. Anat Embryol (Berl) 2005; 210(5-6): 519-23.
109. Hurlemann R, Matusch A, Kuhn KU, Berning J, Elmenhorst D, Winz O, et al. 5-HT2A receptor density is decreased in the at-risk mental state. Psychopharmacology (Berl) 2008; 195(4): 579-90.
110. Erritzoe D, Rasmussen H, Kristiansen KT, Frokjaer VG, Haugbol S, Pinborg L, et al. Cortical and subcortical 5-HT2A receptor binding in neuroleptic-naive first-episode schizophrenic patients. Neuropsychopharmacology 2008; 33(10): 2435-41.
111. Tauscher J, Kapur S, Verhoeff NP, Hussey DF, Daskalakis ZJ, Tauscher-Wisniewski S, et al. Brain serotonin 5-HT(1A) receptor binding in schizophrenia measured by positron emission tomo-graphy and [11C]WAY-100635. Arch Gen Psychiatry 2002; 59(6): 514-20.
112. Yasuno F, Suhara T, Ichimiya T, Takano A, Ando T, Okubo Y. Decreased 5-HT1A receptor binding in amygdala of schizophrenia. Biol Psychiatry 2004; 55(5): 439-44.
113. Bantick RA, Montgomery AJ, Bench CJ, Choudhry T, Malek N, McKenna PJ, et al. A positron emission tomography study of the 5-HT1A receptor in schizophrenia and during clozapine treatment. J Psychopharmacol 2004; 18(3): 346-54.
114. Frankle WG, Lombardo I, Kegeles LS, Slifstein M, Martin JH, Huang Y, et al. Serotonin 1A receptor availability in patients with schizophrenia and schizo-affective disorder: a positron emission tomography imaging study with [11C]WAY 100635. Psychopharmacology (Berl) 2006; 189(2): 155-64.
115. Frankle WG, Narendran R, Huang Y, Hwang DR, Lombardo I, Cangiano C, et al. Serotonin transporter availability in patients with schizophrenia: a positron emission tomography imaging study with [11C]DASB. Biol Psychiatry 2005; 57(12): 1510-6.
116. Pepeu G, Giovannini MG. Cholinesterase inhibitors and beyond. Curr Alzheimer Res 2009; 6(2): 86-96.
117. Meltzer CC, Smith G, DeKosky ST, Pollock BG, Mathis CA, Moore RY, et al. Serotonin in aging, late-life depression, and Alzheimer's disease: the emerging role of functional imaging. Neuropsychopharmacology 1998; 18(6): 407-30.
118. Blin J, Baron JC, Dubois B, Crouzel C, Fiorelli M, Attar-Lévy D, et al. Loss of brain 5-HT2 receptors in Alzheimer's disease. In vivo assessment with positron emission tomography and [18F] setoperone. Brain 1993; 116 (Pt 3): 497-510.
119. [119] Meltzer CC, Price JC, Mathis CA, Greer PJ, Cantwell MN, Houck PR PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders. Am J Psychiatry 1999; 156(12): 1871-8.
120. Hasselbalch SG, Madsen K, Svarer C, Pinborg LH, Holm S, Paulson OB, et al. Reduced 5-HT2A receptor binding in patients with mild cognitive impairment. Neurobiol Aging 2008; 29(12): 1830-8.
121. Santhosh L, Estok KM, Vogel RS, Tamagnan GD, Baldwin RM, Mitsis EM, et al. Regional distribution and behavioral correlates of 5-HT(2A) receptors in Alzheimer's disease with [(18)F] deuteroaltanserin and PET. Psychiatry Res 2009; 173(3): 212-7.
122. Kepe V, Barrio JR, Huang SC, Ercoli L, Siddarth P, Shoghi-Jadid K, et al. Serotonin 1A receptors in the living brain of Alzheimer's disease patients. Proc Natl Acad Sci USA 2006; 103(3): 702-7.
123. Lanctôt KL, Hussey DF, Herrmann N, Black SE, Rusjan PM, Wilson AA, et al. A positron emission tomography study of 5-hydroxytryptamine-1A receptors in Alzheimer disease. Am J Geriatr Psychiatry 2007; 15(10): 888-98.
124. Truchot L, Costes SN, Zimmer L, Laurent B, Le Bars D, Thomas-Antérion C, et al. Up-regulation of hippocampal serotonin metabolism in mild cognitive impairment. Neurology 2007; 69(10): 1012-7.
125. Truchot L, Costes N, Zimmer L, Laurent B, Le Bars D, Thomas-Antérion C, et al. A distinct [18F]MPPF PET profile in amnestic mild cognitive impairment compared to mild Alzheimer's disease. Neuroimage 2008; 40(3): 1251-6.
126. Ouchi Y, Yoshikawa E, Futatsubashi M, Yagi S, Ueki T, Nakamura K. Altered brain serotonin transporter and associated glucose metabolism in Alzheimer disease. J Nucl Med 2009; 50(8): 1260-6.
127. Toczek MT, Carson RE, Lang L, Ma Y, Spanaki MV, Der MG, et al. PET imaging of 5-HT1A receptor binding in patients with temporal lobe epilepsy. Neurology 2003; 60(5): 749-56.
128. Savic I, Lindström P, Gulyás B, Halldin C, Andrée B, Farde L. Limbic reductions of 5-HT1A receptor binding in human temporal lobe epilepsy. Neurology 2004; 62(8): 1343-51.
129. [129] Ito S, Suhara T, Ito H, Yasuno F, Ichimiya T, Takano A, et al. Changes in central 5-HT(1A) receptor binding in mesial temporal epilepsy measured by positron emission tomography with [(11)C]WAY100635. Epilepsy Res 2007; 73(1): 111-8.
130. Giovacchini G, Toczek MT, Bonwetsch R, Bagic A, Lang L, Fraser C, et al. 5-HT 1A receptors are reduced in temporal lobe epilepsy after partial-volume correction. J Nucl Med 2005; 46(7): 1128-35.
131. Theodore WH, Hasler G, Giovacchini G, Kelley K, Reeves-Tyer P, Herscovitch P, et al. Reduced hippocampal 5HT1A PET receptor binding and depression in temporal lobe epilepsy. Epilepsia 2007; 48(8): 1526-30.
132. Hasler G, Bonwetsch R, Giovacchini G, Toczek MT, Bagic A, Luckenbaugh DA, et al. 5-HT1A receptor binding in temporal lobe epilepsy patients with and without major depression. Biol Psychiatry 2007; 62(11): 1258-64.
133. Lothe A, Didelot A, Hammers A, Costes N, Saoud M, Gilliam F, et al. Comorbidity between temporal lobe epilepsy and depression: a [18F]MPPF PET study. Brain 2008; 131(Pt 10): 2765-82.
134. Theodore WH, Giovacchini G, Bonwetsch R, Bagic A, Reeves-Tyer P, Herscovitch P, et al. The effect of antiepileptic drugs on 5-HT-receptor binding measured by positron emission tomography. Epilepsia 2006; 47(3): 499-503.
135. Didelot A, Ryvlin P, Lothe A, Merlet I, Hammers A, Mauguière F. PET imaging of brain 5-HT1A receptors in the preoperative evaluation of temporal lobe epilepsy. Brain 2008; 131(Pt 10): 2751-64.
136. Liew CJ, Lim YM, Bonwetsch R, Shamim S, Sato S, Reeves-Tyer P, et al. 18F-FCWAY and 18F-FDG PET in MRI-negative temporal lobe epilepsy. Epilepsia 2009; 50(2): 234-9.
137. Kaye WH, Frank GK, Meltzer CC, Price JC, McConaha CW, Crossan PJ, et al. Altered serotonin 2A receptor activity in women who have recovered from bulimia nervosa. Am J Psychiatry 2001; 158(7): 1152-5.
138. Frank GK, Kaye WH, Meltzer CC, Price JC, Greer P, McConaha C, et al. Reduced 5-HT2A receptor binding after recovery from anorexia nervosa. Biol Psychiatry 2002; 52(9): 896-906.
139. [139] Bailer UF, Price JC, Meltzer CC, Mathis CA, Frank GK, Weissfeld L, et al. Altered 5-HT(2A) receptor binding after recovery from bulimia-type anorexia nervosa: relationships to harm avoidance and drive for thinness. Neuropsychopharmacology 2004; 29(6): 1143-55.
140. Bailer UF, Frank GK, Henry SE, Price JC, Meltzer CC, Mathis CA, et al. Exaggerated 5-HT1A but normal 5-HT2A receptor activity in individuals ill with anorexia nervosa. Biol Psychiatry 2007; 61(9): 1090-9.
141. Bailer UF, Frank GK, Henry SE, Price JC, Meltzer CC, Becker C, et al. Serotonin transporter binding after recovery from eating disorders. Psychopharmacology (Berl) 2007; 195(3): 315-24.
142. Bailer UF, Frank GK, Henry SE, Price JC, Meltzer CC, Weissfeld L, et al. Altered brain serotonin 5-HT1A receptor binding after recovery from anorexia nervosa measured by positron emission tomography and [carbonyl11C]WAY-100635. Arch Gen Psychiatry 2005; 62(9): 1032-41.
143. Galusca B, Costes N, Zito NG, Peyron R, Bossu C, Lang F, et al. Organic background of restrictive-type anorexia nervosa suggested by increased serotonin 1A receptor binding in right frontotemporal cortex of both lean and recovered patients: [18F]MPPF PET scan study. Biol Psychiatry 2008; 64(11): 1009-13.
144. Meyer JH, Wilson AA, Rusjan P, Clark M, Houle S, Woodside S, et al. Serotonin2A receptor binding potential in people with aggressive and violent behaviour. J Psychiatr Neurosci 2008; 33(6): 499-508.
145. Soloff PH, Price JC, Meltzer CC, Fabio A, Frank GK, Kaye WH. 5HT2A receptor binding is increased in borderline personality disorder. Biol Psychiatry 2007; 62(6): 580-7.
146. Frankle WG, Lombardo I, New AS, Goodman M, Talbot PS, Huang Y, et al. Brain serotonin transporter distribution in subjects with impulsive aggressivity: a positron emission study with [11C]McN 5652. Am J Psychiatry 2005; 162(5): 915-23.
147. Witte AV, Flöel A, Stein P, Savli M, Mien LK, Wadsak W, et al. Aggression is related to frontal serotonin-1A receptor distribution as revealed by PET in healthy subjects. Hum Brain Mapp 2009; 30(8): 2558-70.
148. Jovanovic H, Lundberg J, Karlsson P, Cerin A, Saijo T, Varrone A, et al. Sex differences in the serotonin 1A receptor and serotonin transporter binding in the human brain measured by PET. Neuroimage 2008; 39(3): 1408-19.
149. Stein P, Savli M, Wadsak W, Mitterhauser M, Fink M, Spindelegger C, et al. The serotonin-1A receptor distribution in healthy men and women measured by PET and [carbonyl-Investigating Serotonergic Function Using Positron Emission Tomography 11C]WAY-100635. Eur J Nucl Med Mol Imaging 2008; 35(12): 2159-68.
150. Fink M, Wadsak W, Savli M, Stein P, Moser U, Hahn A, et al. Lateralization of the serotonin-1A receptor distribution in language areas revealed by PET. Neuroimage 2009; 45(2): 598-605.
151. Lothe A, Boni C, Costes N, Gorwood P, Bouvard S, Le Bars D, et al. Association between triallelic polymorphism of the serotonin transporter and [18F]MPPF binding potential at 5-HT1A receptors in healthy subjects. Neuroimage 2009; 47(2): 482-92.
152. Erritzoe D, Frokjaer VG, Haugbol S, Marner L, Svarer C, Holst K, et al. Brain serotonin 2A receptor binding: relations to body mass index, tobacco and alcohol use. Neuroimage 2009; 46(1): 23-30.
153. Ruhé HG, Booij J, Reitsma JB, Schene AH. Serotonin transporter binding with [123I]beta-CIT SPECT in major depressive disorder Received: March 2, 2010 Accepted: April 1, 2010 versus controls: effect of season and gender.Eur J Nucl Med Mol Imaging 2009; 36(5): 841-9.
154. Henningsson S, Borg J, Lundberg J, Bah J, Lindström M, Ryding E, et al. Genetic variation in brain-derived neurotrophic factor is associated with serotonin transporter but not serotonin-1A receptor availability in men. Biol Psychiatry 2009; 66(5): 477-85.
155. Praschak-Rieder N, Willeit M, Wilson AA, Houle S, Meyer JH. Seasonal variation in human brain serotonin transporter binding. Arch Gen Psychiatry 2008; 65(9): 1072-8.
156. Kalbitzer J, Frokjaer VG, Erritzoe D, Svarer C, Cumming P, Nielsen FA, et al. The personality trait openness is related to cerebral 5-HTT levels. Neuroimage 2009; 45(2): 280-5.